BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Telaprevir: Phase II started

Vertex began a Phase II trial to evaluate twice-daily 100 or 400 mg VX-222 plus telaprevir with or without Pegasys peginterferon alfa-2a and ribavirin in 100 treatment-naïve patients with HCV genotype 1. Patients with undetectable HCV RNA levels after 12 weeks will stop treatment,...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >